International Headache Society (@ihs_official) header
International Headache Society (@ihs_official) profile picture

To advance headache science, education & treatment. Our Journal: @JCephalalgia. Find us on https://xitter.gq/t.co/wjNPoTFjTr…

London, United Kingdom
Joined November 2014
Photo by International Headache Society (@ihs_official)Photo by International Headache Society (@ihs_official)Photo by International Headache Society (@ihs_official)Photo by International Headache Society (@ihs_official)Photo by International Headache Society (@ihs_official)Photo by International Headache Society (@ihs_official)Photo by International Headache Society (@ihs_official)Photo by International Headache Society (@ihs_official)Photo by International Headache Society (@ihs_official)Photo by International Headache Society (@ihs_official)
Did you know that headache attributed to IIH has no specific clinical phenotype? It can closely resemble chronic migraine or chronic tension-type headache. Moreover, primary headache disorders may coexist with IIH. The ICHD-3 criteria require: - A new headache or significant worsening of a pre-existing headache. - Confirmed IIH and elevated CSF pressure. - Evidence supporting a temporal or clinical relationship between IIH and headache. - No better alternative ICHD-3 diagnosis. An important clinical consideration: IIH should be diagnosed with caution in patients without papilloedema. In these cases, alternative explanations, including medication-overuse headache, must be carefully considered. **The key message:** identifying IIH is not simply about recognizing a headache pattern. It requires integrating clinical findings, ophthalmological assessment, neuroimaging and CSF pressure measurements. #Migraine #HeadacheDisorders #ichd3matters
3
118
New in Cephalalgia! • Long-term treatment of atogepant for the preventive treatment of migraine was safe and well tolerated. Overall safety results across 156 weeks were consistent with the known safety profile of atogepant; no new safety signals were observed. • Efficacy and functional outcomes showed improvement from lead-in study baseline at weeks 13–16 and were consistent through 156 weeks. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience
2
4
242
New in Cephalalgia! In this real-world case series, gepants were associated with clinically meaningful reductions in attack frequency in patients with active cluster headache bouts, with good short-term tolerability. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience
2
3
320
New in Cephalalgia! Atogepant showed rapid reductions in headache burden within one week in episodic cluster headache. Improvements across outcomes support its potential as an early preventive option in real-world practice. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience
124
New in Cephalalgia! Management must move beyond reducing attack frequency to standardizing measures that capture and treat the full spectrum of pain-free disability. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience
1
3
7
367
New in Cephalalgia! Rimegepant provides 2-hour pain freedom in nearly half of treated migraine attacks, with a consistent response across repeated attacks in a meaningful proportion of individuals. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience
142
New in Cephalalgia! Post-hoc analyses in 234 women with suspected/confirmed hypertensive disorders of pregnancy (HDP) showed no association between migraine and sFlt-1, PlGF, or their ratio within HDP groups, yet differences were seen in the overall population journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience
143
📣 Deadline extended: Complimentary registrations for IHS members! The ACEFAPERU Headache Summit 2026 will take place online on 26–28 November 2026. ACEFAPERU is offering complimentary registrations to IHS members, allocated on a first-come, first-served basis, with priority given to junior members. 📅 Extended application deadline: 20 November 2026 📧 To apply, email: [email protected] To learn more, please go to: ihs-headache.org/en/events/a…
2
5
279
New in Cephalalgia! A 10-year study developed and externally validated the Migraine Risk Stratification Score (MRSS) to stratify cryptogenic ischemic stroke (CIS) risk in patients with migraine and right-to-left shunt, with particular value for identifying individuals at low risk. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience
1
207
New in Cephalalgia! Across all countries, substantial humanistic and economic burden was reported in individuals with migraine and comorbid depression compared with individuals with migraine alone, emphasizing the need for comprehensive management and preventive strategies to cohesively address both conditions journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience
2
135
New in Cephalalgia Reports! 🧠 How much can we learn about a headache simply by asking the right questions? When it comes to headache disorders, a good clinical history is often our most powerful diagnostic tool. But effective history-taking is more than ticking boxes. It requires active listening, empathy, structured questioning, and clinical reasoning. 📢 A new article published in Cephalalgia Reports by the International Headache Society Education Committee presents a practical approach to optimising headache history-taking: 1️⃣ Listen and connect: Build rapport, ask open-ended questions, and understand the patient's experience. 2️⃣ Characterise the headache: Explore the onset, timing, pain characteristics, associated symptoms, triggers, and impact on daily life. 3️⃣ Check for red flags: Identify warning signs of secondary headaches using tools such as SNNOOP10 and careful assessment of temporal patterns. 4️⃣ Explain and plan: Communicate the diagnosis, address patient concerns, and develop a shared management plan. 💡 The key message? Headache diagnosis is not just about recognising symptoms. It is about understanding the person experiencing them. And while digital tools and AI may support clinical assessment, they cannot replace the art of listening. 📖 Read the full paper: Souza MNP, et al. Optimizing headache history-taking: A structured approach from the International Headache Society Education Committee. Cephalalgia Reports. 2026;9. 🔗 doi.org/10.1177/251581632614… 💬 For clinicians: What is the one question you never forget to ask when taking a headache history? #CephalalgiaReports #HeadacheMedicine #Migraine #Neurology #HeadacheEducation #InternationalHeadacheSociety #MedicalEducation
1
129
New in Cephalalgia! Some other headache was unaccounted for in these studies; moreover, it was common: the Turkish study, with 7,088 participants, estimated its 1-year prevalence as 29.2%.6 The study authors labelled it “undifferentiated headache” (UdH) (in terminological alignment with A3.6 Undifferentiated trigeminal autonomic cephalalgia in ICHD-3). journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience
3
260
New in Cephalalgia! The evidence cited in the letter supports giving UdH greater attention in future population studies and burden estimates. At the same time, its clinical course and the benefits of any specific intervention require further study. The authors therefore regard UdH as an important research and public health consideration, without assuming that every child with brief or mild headache requires treatment. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience
1
5
252
New in Cephalalgia! The authors encourage colleagues within the international orofacial pain and oral medicine communities, to evaluate our proposed criteria through independent validation studies and multicenter collaborative research. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience
3
229
New in Cephalalgia! This Letter discusses how discordant negative-control outcomes should be interpreted when assessing residual bias in the cerebrovascular safety evaluation of CGRP monoclonal antibodies. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience
1
7
291
New in Cephalalgia! Both negative-control findings should inform interpretation, without treating the fracture result as confirmation of exchangeability or the UTI result as a quantitative measure of bias in the primary outcome. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience @BradleyOngMD
3
239
New in Cephalalgia Reports! Headache disorders are a leading cause of disability, yet publicly funded headache clinical trials in Australia are remarkably scarce. This new paper highlights the gap and the opportunity for change. Article highlights • No funded clinical trials were identified for migraine or tension-type headache, despite their substantial burden. • A review of NHMRC and MRFF funding in Australia identified only one funded headache disorder clinical trial since 2013, focused on cluster headache. • Increased investment in headache clinical trials, workforce development, and national research infrastructure could help accelerate evidence generation and improve patient outcomes. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience
1
190
📣 10 Complimentary Registrations for IHS Members! The ACEFAPERU Headache Summit 2026 will be held online on 26–28 November 2026. ACEFAPERU is offering 10 complimentary registrations to IHS members. Places are available on a first-come, first-served basis, with priority given to junior members. 📅 Application deadline: 16 November 2026 📧 To apply, email: [email protected] Learn more: ihs-headache.org/en/events/a…
2
1
274
New in Cephalalgia Reports! Can rheumatoid meningitis mask itself as a simple worsening of pre-existing migraine with aura? Yes, even without focal signs! Read how calculating the serum anti-CCP antibody (ACPA) index via the Reiber equation cracked this diagnostic puzzle. journals.sagepub.com/doi/10.… #migraine #headache #brain #pain #neurology #neuroscience
3
311
📢 Call for Papers: Jes Olesen Awards for the Advancement of Headache Medicine 🧠🏆 Submissions are now open! Cephalalgia invites researchers worldwide to submit their original research for the Jes Olesen Awards, recognising excellence and innovation in headache medicine. 🏆 Two prestigious awards: 🔬 Jes Olesen Basic Science Award 🩺 Jes Olesen Clinical Science Award Each award includes: 💶 €10,000 prize 🌍 Recognition through Cephalalgia and IHS platforms 🎤 Opportunity to present at a major scientific meeting ✅ Eligibility: • Original research papers only • First author must be under 45 years of age at submission • One submission per participant 📅 Submission deadline: 28 February 2027 📄 All submissions will undergo Cephalalgia's standard peer-review process, with winners selected from accepted papers by an expert panel. The awards are generously funded by Professor Jes Olesen through JO Health to support and inspire the next generation of headache researchers. 🔗 Submit your research: mc.manuscriptcentral.com/cep… More details: journals.sagepub.com/page/ce… Don't miss this opportunity to have your research recognised! #JesOlesenAwards #Cephalalgia #IHS #HeadacheResearch #HeadacheMedicine #CallForPapers #headache
1
215